GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Cash Conversion Cycle

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Cash Conversion Cycle : 162.84 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Maravai LifeSciences Holdings's Days Sales Outstanding for the three months ended in Mar. 2024 was 64.9.
Maravai LifeSciences Holdings's Days Inventory for the three months ended in Mar. 2024 was 120.5.
Maravai LifeSciences Holdings's Days Payable for the three months ended in Mar. 2024 was 22.56.
Therefore, Maravai LifeSciences Holdings's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 162.84.


Maravai LifeSciences Holdings Cash Conversion Cycle Historical Data

The historical data trend for Maravai LifeSciences Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Cash Conversion Cycle Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial 90.96 117.34 127.46 139.96 217.54

Maravai LifeSciences Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 230.65 165.41 164.66 166.18 162.84

Competitive Comparison of Maravai LifeSciences Holdings's Cash Conversion Cycle

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maravai LifeSciences Holdings's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Cash Conversion Cycle falls into.



Maravai LifeSciences Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Maravai LifeSciences Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=122.04+116.01-20.51
=217.54

Maravai LifeSciences Holdings's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=64.9+120.5-22.56
=162.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maravai LifeSciences Holdings  (NAS:MRVI) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Maravai LifeSciences Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Executives
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii officer: See remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy officer: See Remarks 1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull director, officer: Chief Executive Officer 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack officer: General Counsel 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121